Dr. Shain Discusses Emerging Agents in Multiple Myeloma

Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses emerging agents in multiple myeloma.

Oprozomib, an oral agent, is an irreversible proteasome inhibitor that has shown good activity in highly refractory patients.

Additionally, there is marizomib, another proteasome inhibitor that is being looked at alone and in combinations. It still requires further study—but it is something exciting that is on the horizon, says Shain.